We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Polyphosphates May Be the Key to Preventing Thrombosis

By LabMedica International staff writers
Posted on 22 Dec 2009
Researchers have demonstrated that an inorganic polymer, polyphosphate, plays a key role in both inflammation and the formation of blood clots.

Polyphosphates are produced and released by platelets (thrombocytes). More...
They play a key role in blood coagulation, as they activate factor XII, which is essential for blood clot formation. Furthermore, platelet-derived polyphosphates activate a variety of inflammatory substances that contribute to leakage from the blood vessels, which is a characteristic feature of inflammation.

Investigators at the University of Leeds (United Kingdom) and collaborators from several European countries and the United States reported in the December 11, 2009, issue of the journal Cell that activated platelets released inorganic polyphosphate (polyP), a polymer of 60–100 phosphate residues that directly bound to and activated the plasma protease factor XII. Blood clots initiated by polyP formed inside blood vessels (causing thrombosis), but not on the surface of the skin. For this reason the investigators postulate that intervention to prevent polyP formation or factor XII activation could prevent thrombosis without interfering with the healing of wounds.

"Our work suggests polyphosphate or factor XII could be potential new targets, as neither seems to affect our ability to heal naturally, so drugs based on these molecules could offer a major improvement on existing treatments," said contributing author Dr. Nicola Mutch, an independent research fellow at the University of Leeds. "The challenge in designing treatments to reduce thrombosis is getting the balance right. We need to find an appropriate drug level or target which causes enough anticoagulation to prevent risk of heart attack or stroke but with minimal bleeding side effects."

Related Links:
University of Leeds



New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
New
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The method that profiles DNA methylation in cell-free DNA from a single blood sample to detect disease signals system-wide (photo courtesy of Shutterstock)

cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample

Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read more

Immunology

view channel
Image: Mycobacterium tuberculosis bacteria seen with a scanning electron microscope (Credit: CDC PHIL)

Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection

Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more

Pathology

view channel
Image: Spatial characterization of immune–tumor interactions and treatment response across SCLC and extended phenotype models (Cristian Barrera et al, npj Precision Oncology (2026). DOI: 10.1038/s41698-025-01225-9)

AI Pathology Tool Predicts Chemotherapy Response in Small Cell Lung Cancer

Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.